P. Burch
New England Journal of Medicine · 2004–2017
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Whom P. Burch trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- D. Gabrilovich (in Immunology)
Papers from P. Burch's perspective
Ordered by how strongly the researchers P. Burch trusts endorse each paper. Same corpus, a different order for every researcher.
- A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. (Journal of the National Cancer Institute)
- Signatures of mutational processes in human cancer (Nature)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (Nature)
- Mechanisms and functional significance of tumour-induced dendritic-cell defects (Nature reviews. Immunology)
- Whole genomes redefine the mutational landscape of pancreatic cancer (Nature)
- Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. (Journal of Clinical Oncology)
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets (Nature Communications)
- Genomic analyses identify molecular subtypes of pancreatic cancer (Nature)
- Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma
- Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy (Nature Medicine)
Their papers
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma (2017) — 1,688 citations
- Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009) — 845 citations
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (2004) — 3,752 citations